ArticleThe Lancet. Rheumatology2023

Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study.

Md Yuzaiful Md Yusof et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.